These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23244673)

  • 1. Outcomes in men with large prostates (≥ 60 cm(3)) treated with definitive proton therapy for prostate cancer.
    McGee L; Mendenhall NP; Henderson RH; Morris CG; Nichols RC; Marcus RJ; Li Z; Mendenhall WM; Williams CR; Hoppe BS
    Acta Oncol; 2013 Apr; 52(3):470-6. PubMed ID: 23244673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer.
    Mendenhall NP; Li Z; Hoppe BS; Marcus RB; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Costa J; Henderson R
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):213-21. PubMed ID: 21093164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials.
    Henderson RH; Hoppe BS; Marcus RB; Mendenhall WM; Nichols RC; Li Z; Su Z; Morris CG; Williams CR; Costa J; Mendenhall NP
    Acta Oncol; 2013 Apr; 52(3):463-9. PubMed ID: 23477359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
    Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
    Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute morbidity of proton therapy for prostate cancer: the Hyogo Ion Beam Medical Center experience.
    Mayahara H; Murakami M; Kagawa K; Kawaguchi A; Oda Y; Miyawaki D; Sasaki R; Sugimura K; Hishikawa Y
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):434-43. PubMed ID: 17482768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.
    Bryant C; Smith TL; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Su Z; Li Z; Lee D; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):422-434. PubMed ID: 27084658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.
    Deville C; Jain A; Hwang WT; Woodhouse KD; Both S; Wang S; Gabriel PE; Christodouleas JP; Bekelman J; Tochner Z; Vapiwala N
    Acta Oncol; 2018 Nov; 57(11):1506-1514. PubMed ID: 30028227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy: first clinical trial of proton beam therapy for prostate cancer in Japan.
    Nihei K; Ogino T; Ishikura S; Kawashima M; Nishimura H; Arahira S; Onozawa M
    Jpn J Clin Oncol; 2005 Dec; 35(12):745-52. PubMed ID: 16314345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy.
    Aizer AA; Anderson NS; Oh SC; Yu JB; McKeon AM; Decker RH; Peschel RE
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):379-84. PubMed ID: 20452135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
    Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose intensity-modulated radiation therapy as primary treatment of prostate cancer: genitourinary/gastrointestinal toxicity and outcomes, a single-institution experience.
    Detti B; Baki M; Becherini C; Saieva C; Scartoni D; Giacomelli I; Trombetta L; Muntoni C; Olmetto E; Francolini G; Turkaj A; Topulli J; Ciabatti C; Carta G; Poggesi L; Delli Paoli C; Terziani F; Grassi R; Livi L
    Radiol Med; 2019 May; 124(5):422-431. PubMed ID: 30607866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The results of real-time brachytherapy for the management of low- and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mL.
    Dallas NL; Malone PR; Jones A; Doggart AJ; McConway KJ; Rogers PB
    BJU Int; 2012 Aug; 110(3):383-90. PubMed ID: 22332791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse effects of androgen deprivation therapy on persistent genitourinary complications after carbon ion radiotherapy for prostate cancer.
    Ishikawa H; Tsuji H; Kamada T; Hirasawa N; Yanagi T; Mizoe JE; Akakura K; Suzuki H; Shimazaki J; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):78-84. PubMed ID: 18456419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.